XOMA (NASDAQ:XOMA) Given Buy Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of XOMA (NASDAQ:XOMA) in a research report sent to investors on Friday morning,Benzinga reports. HC Wainwright currently has a $123.00 price target on the biotechnology company’s stock.

XOMA Price Performance

Shares of XOMA stock opened at $27.15 on Friday. The company has a quick ratio of 7.52, a current ratio of 7.52 and a debt-to-equity ratio of 1.28. XOMA has a fifty-two week low of $15.56 and a fifty-two week high of $35.00. The stock’s 50-day moving average is $30.05 and its two-hundred day moving average is $27.67.

Insider Activity

In related news, CEO Owen Hughes sold 21,881 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $29.95, for a total value of $655,335.95. Following the completion of the sale, the chief executive officer now directly owns 34,979 shares in the company, valued at approximately $1,047,621.05. The trade was a 38.48 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 7.20% of the stock is owned by insiders.

Institutional Trading of XOMA

A number of institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets raised its holdings in XOMA by 95.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 795 shares during the period. Price T Rowe Associates Inc. MD bought a new position in XOMA in the 1st quarter worth approximately $212,000. Rhumbline Advisers grew its stake in shares of XOMA by 16.0% in the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock worth $230,000 after acquiring an additional 1,334 shares during the last quarter. Barclays PLC raised its stake in XOMA by 300.7% during the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after purchasing an additional 8,447 shares during the last quarter. Finally, Ellsworth Advisors LLC acquired a new stake in XOMA in the 3rd quarter worth $516,000. 95.92% of the stock is currently owned by institutional investors and hedge funds.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.